COVID-19: Pharmidex Contingency Plan
March 19, 2020

Pharmidex are taking all the necessary steps to ensure the progression of client studies during these difficult time.

COVID-19: Pharmidex Contingency Plan


We are taking all necessary steps to ensure that studies proceed, while preserving the health and safety of staff. Summary of key steps taken at Pharmidex:


- Following the relevant guidelines issued by Public Health England.


- Limiting access to only essential people in our laboratories and cancelling/rescheduling all non-critical visitors. All visitors must confirm COVID-19 status prior to arrival.


- Cancelled all non-essential business travel.


- Closely communicating with suppliers regarding the status of their inventories and their business continuity plans and identifying alternate sources for supplies.


- Implemented strict sanitization practices to prevent cross contamination between staff, including providing our staff with resources and up-to-date information and guidance.


- To prevent the potential spread of the infection amongst employees, staff will declare any potential close contact with infected individuals and follow the relevant health guidelines.


- Our operations team will ensure adequate staffing cover so as not to compromise client studies.


We will keep you updated if the situation changes resulting in any impact on progression of your projects.


Best wishes to everyone during these tough times.

April 1, 2026
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: ๐Ÿ”ฌ Preclinical in vivo pharmacology ๐Ÿงช Bioanalysis (LC–MS/MS, qPCR, ELISA) ๐Ÿ“Š Translational and mechanistic studies ๐Ÿงซ Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
March 26, 2026
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: ๐Ÿ“„ “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" ๐Ÿ“„ “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. ๐Ÿ”— Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
More Posts